ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1672774
This article is part of the Research TopicPrecision Oncology: Integrating Molecular Mechanisms, Organoid Models, and Omics Technologies for Personalized Cancer CareView all 3 articles
Multilocus Inherited Neoplasia Allele Syndrome (MINAS) in a Turkish Cohort: Molecular Insights and Clinical Relevance for Precision Oncology
Provisionally accepted
Taha Bahsi1,2,3*
Serhat Seyhan1,2,3Kaan Helvaci2Umut Demirci2Irem Bilge Tekin2Selami Bayram4Mehmet Akif Ozturk5Fatih Aydogan6Serkan Keskin5Kezban Pilanci7Nur Sener5Murat Tatlı4Hakan Harputluoglu7Esat Namal5Aysegul Kargi4Mukremin Uysal4Mahmut Ilhan2Cihan Erol2Naziyet Kose2Kerem Okutur5Halit Karaca2Erkan Dogan5Veli Berk2Ahmet Siyar Ekinci2Mustafa Ozdogan4,7- 1Üsküdar University, Üsküdar, Türkiye
- 2Memorial Health Group, Ankara, Türkiye
- 3Department of Medical Genetics, MedRoyal Genetic Disease Evaluation Center, Memorial Healthcare Group, Istanbul, Türkiye
- 4Memorial Health Group Antalya, Antalya, Türkiye
- 5Memorial Health Group Istanbul, Istanbul, Türkiye
- 6Memorial Bahcelievler Hospital, Istanbul, Türkiye
- 7Memorial Health Group, Istanbul, Türkiye
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract Background: Multilocus Inherited Neoplasia Allele Syndrome (MINAS) describes individuals who harbor pathogenic or likely pathogenic (LP/P) germline variants in two or more distinct cancer predisposition genes. With the broader implementation of next-generation sequencing (NGS) and multigene panel testing, MINAS has been increasingly recognized. Methods: We retrospectively evaluated 655 Turkish patients referred for hereditary cancer testing using two validated NGS panels. MINAS was defined as the presence of LP/P variants in at least two different genes. Results: 14 patients (2.13%) met the criteria for MINAS. An additional 156 patients (23.8%) had single-gene LP/P variants. MINAS cases accounted for 8.2% of mutation-positive individuals. These patients showed diverse tumor types. Common gene combinations included BRCA1+MUTYH and CHEK2+PALB2. Conclusion: This is the first MINAS-focused analysis from a Turkish cohort. Although uncommon, MINAS represents a significant subset of genetically high-risk individuals requiring tailored clinical management.
Keywords: MINAS, Germline variants, Multigene panel, BRCA, Turkish cohort, Hereditary cancer
Received: 24 Jul 2025; Accepted: 17 Oct 2025.
Copyright: © 2025 Bahsi, Seyhan, Helvaci, Demirci, Tekin, Bayram, Ozturk, Aydogan, Keskin, Pilanci, Sener, Tatlı, Harputluoglu, Namal, Kargi, Uysal, Ilhan, Erol, Kose, Okutur, Karaca, Dogan, Berk, Ekinci and Ozdogan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Taha Bahsi, tahabahsi@yahoo.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.